Frank Laukien is the Chairman, President and CEO of Bruker Corporation and he is also President of Bruker Daltonics. Dr. Laukien holds a B.Sc. in physics from MIT, and a Ph.D. in chemical physics from Harvard University. Throughout his 20 year business career, he has taken numerous courses and done extensive reading in business, innovation and R&D management, accounting and corporate finance as well as in business, corporate and IP law. He has been a part-time professor at the Swammerdam Institute for Life Sciences (SILS) of the University of Amsterdam, and in 2002-03 served as Chairman of the Analytical & Life Science Systems Association. He is a Trustee of the Rivers School in Weston, MA.
Dr. Fesik is currently a Professor in the Department of Biochemistry at Vanderbilt University School of
Medicine. He is also a member of the Vanderbilt–Ingram Cancer Center, the Institute of Chemical
Biology and the Center for Structural Biology. Prior to joining the Vanderbilt faculty in May 2009, Dr.
Fesik was the Divisional Vice President of Cancer Research of Abbott Laboratories, a global, broad based
health care company. Dr. Fesik joined Abbott Laboratories in 1983 and served in various research and
scientific capacities. From 2003 to 2006, Dr. Fesik served as a member of the Scientific Advisory Board
of the Bruker BioSpin Group. In 2003 he was awarded a lifetime achievement award in nuclear magnetic
resonance by the Eastern Analytical Society and also was named a Distinguished Research Fellow of
Abbott Laboratories’ Volwiler Society. Dr. Fesik has received numerous awards for his scientific research
and scholarship and currently serves on a number of research and scientific advisory boards. Dr. Fesik
holds a Ph.D. in Medicinal Chemistry from the University of Connecticut and has postdoctoral training at
Yale University. Dr. Fesik brings both scientific and executive expertise to the board, with extensive
research and advisory experience across multiple sectors, including various corporate, academic and
institute laboratories. Dr. Fesik serves on the Company’s Compensation Committee.
Dr. Friend currently serves as Director of the Rowland Institute at Harvard University. She also serves as Director of the DoE Energy Frontier Research Center for Sustainable Catalysis at Harvard. In 2011-2012, Dr. Friend was the Associate Director of the SLAC National Accelerator Laboratory. From 2001-2011, she was the Associate Director of the Materials Research Science and Engineering Center, from 2004-2007, she was the Chair of the Chemistry and Chemical Biology Department, and from 2002-2005, she was Associate Dean of the Faculty of Arts & Sciences, all at Harvard University.
Dr. Friend became the Theodore Williams Richards Professor of Chemistry in 1998 and a Professor of Materials Science in 2002 at Harvard University. Since joining the Harvard Department of Chemistry in 1982, she has received numerous awards for her scientific research, and has served on a number of research and scientific advisory boards and panels. Dr. Friend holds a Ph.D. in Chemistry from the University of California, Berkeley.
Chris van Ingen has served as an advisor to various life sciences technology companies since 2007, including Bruker and certain of its subsidiaries from 2008 until 2011. Mr. van Ingen also served as a director of Bruker Energy & Supercon Technologies, Inc. from 2009 until April 2013, including as chairman of the board of directors and as a member of the Compensation Committee from 2010 to March 2013. From 2001 until October 2007, he was President of the Life Sciences and Chemical Analysis Group at Agilent Technologies, Inc. Prior to joining Agilent, Mr. van Ingen was Vice President of Sales and Marketing at Hewlett Packard’s Chemical Analysis Group and held other senior management positions at Hewlett Packard’s Avondale Division and Netherlands Country Operation. Mr. van Ingen currently serves on the boards of directors of the Promega Corporation, and Accelrys, Inc. He was named Chairman of the Board of Directors of Accelrys, Inc. in January 2012 and serves on the audit committee. He previously served as a director of Alpha Innotech, Inc. from June 2009 to October 2009 and Symyx Technologies, Inc. from February 2008 until its merger with Accelrys in July 2010. Mr. van Ingen holds a B.S. degree in analytical chemistry. Mr. van Ingen brings to the Board financial, sales and marketing, and general management experience in the analytical and life sciences industries, as well as significant experience in corporate governance, strategic planning and public company compensation matters. Mr. van Ingen serves on the Company’s Audit Committee and is Chairman of the Company’s BEST Special Committee.
Dr. Kastner currently serves as President of the Science Philanthropy Alliance, whose goal is to increase private funding for fundamental research. He is on leave as Donner Professor of Science at Massachusetts Institute of Technology (‘‘MIT’’), a position he has held since 1989. Since joining the MIT Department of Physics in 1973, Dr. Kastner has served in a variety of senior faculty and
leadership roles at MIT, including as Dean of the MIT School of Science from July 2007 to December 2014, Head of the MIT Department of Physics from 1998 to 2007, Director of MIT’s Center for Materials Science and Engineering from 1993 to 1998 and as Associate Director of MIT’s Consortium
for Superconducting Electronics from 1989 to 1992. Dr. Kastner previously served a term on the Company’s board of directors from February 2013 to May 2014. Dr. Kastner has received numerous awards for his scientific research and scholarship and currently serves on a number of research and
scientific advisory boards. Dr. Kastner holds a Ph.D. in Physics from the University of Chicago. Dr. Kastner brings to the board significant expertise in recent and emerging scientific, technological and research funding trends, as well as in academic and government research markets, from which the Company derives approximately half of its revenues today. Moreover, Dr. Kastner has extensive organizational and management experience in non-profit institutions and insights into U.S. government research management and priorities.
Mr. Kniss joined the Company’s board of directors in July 2003 in connection with the merger of Bruker
Daltonics and Bruker AXS, having served on the Bruker AXS board of directors since June 2001. Mr.
Kniss was Senior Vice President and General Manager for Agilent Technologies, Chemical Analysis
Group, a producer of gas and liquid chromatographs, mass spectrometers and spectrophotometers, from
August 1999 until March 2001. Prior to the spin-off of Agilent from the Hewlett Packard Company, from
1995 to 1999, Mr. Kniss was Vice President and General Manager of the Chemical Analysis Group for
Hewlett Packard. From 2004 to 2008, Mr. Kniss served as chairman of the board of directors of
AviaraDx, Inc. (formerly Arcturus Bioscience, Inc.), a life-science tools company acquired by
BioMerieux. Mr. Kniss holds a B.S. from Brown University and a M.B.A. from Stanford University. Mr.
Kniss has a strong executive background in the life sciences and analytical instruments industries, as well
as experience in corporate governance and public company executive compensation matters. Mr. Kniss is
the chairman of the Company’s Compensation Committee.
Mr. Joerg Laukien has served as Executive Chairman of Bruker BioSpin Corporation since 2010. Until
December 2013, Joerg Laukien was a Managing Director of Bruker BioSpin MRI GmbH since 1997 and
a Managing Director of Bruker BioSpin GmbH since 2011, each of which are subsidiaries of Bruker. Mr.
Joerg Laukien also served as Managing Director of Bruker Elektronik GmbH from 1991 until its merger
with Bruker BioSpin GmbH in 2010, as a director and President of Bruker BioSpin MRI, Inc. from 1997
to 2010 and as a director of Bruker Energy & Supercon Technologies, Inc. from 2008 to March 2013.
Joerg Laukien is the brother of Dr. Frank H. Laukien, the Chairman, President and Chief Executive
Officer of the Company, and half-brother of Dr. Dirk D. Laukien, a former director and former executive
officer of the Company. Joerg Laukien serves as a member of the regional advisory council of Deutsche
Bank AG in Germany. He holds a B.A. from the Verwaltungs- und Wirtschafts-Akademie in Karlsruhe,
Germany. Joerg Laukien brings extensive executive experience within the Company to the board, as well
as experience in financial and strategic planning. Mr. Joerg Laukien serves on the Company’s BEST
Dr. Linton serves as the lead director of our board of directors. He was appointed lead director in March
2004 by the independent members of the board of directors. As lead director, Dr. Linton performs the
usual responsibilities of a lead director including acting as a liaison between management and the board
of directors. Since 1978, Dr. Linton has served as the Chairman, President and Chief Executive Officer of
Promega Corporation, Madison, Wisconsin, a privately held life science supply company founded by Dr.
Linton. Dr. Linton received a B.S. degree from University of California, Berkeley in 1970 and an
honorary Ph.D. from Hannam University (Korea) in 2004. Dr. Linton has been a director of the
Wisconsin Technology Council since 2001 and also serves as a director of ALDA (Analytical, Life
Science & Diagnostics Association), an industry association formerly known as Analytical & Life
Sciences Systems Association, or ALSSA, and Heffter Research Institute, a non-profit medical research
organization, and is President of the BioPharmaceutical Technology Center Institute. Dr. Linton brings to
the board extensive executive, international operations management and technical expertise in the life
sciences industry, as well as significant experience in strategic planning, corporate governance, and public
company executive compensation matters. In addition to serving as lead director, Dr. Linton serves on the
Company’s Nominating Committee.
Dr. Martin is Chairman and Chief Executive Officer of the Eurofins Scientific Group, a Luxembourg-based international life sciences company which provides a range of analytical testing services to clients across multiple industries. Dr. Martin founded the original Eurofins Scientific Nantes food authenticity laboratory in 1988 and is a past President of the French Association of private analytical laboratories, or APROLAB, and the North American Technical Committee for Juice and Juice Products. Dr. Martin holds a Ph.D. in Statistics and Applied Mathematics and a Master of Science from Syracuse University. Dr. Martin brings extensive international business and management experience in the life-science and analytical tools industries to the Board, including specialized expertise in the envienvironmental testing, food safety analysis and pharmaceutical clinical research markets.
Mr. Ornell recently retired from Waters Corporation (NYSE:WAT), where he served as Vice President, Finance and Administration and Chief Financial Officer from 2001 to 2013. During this time at Waters, he was also responsible for information technology, investor relations and the TA Instruments Division. Mr. Ornell joined Waters in 1994 and served there in a variety of operational and financial leadership roles before assuming the position of Chief Financial Officer. During 2014, Mr. Ornell continued to serve Waters on a parttime, transitional basis. Prior to joining Waters, Mr. Ornell progressed through a series of roles of increasing responsibility at a number of multinational corporations, primarily in operational finance functions. Mr. Ornell holds a Master of Business Administration degree from Southern New Hampshire University.
Since November 1999, Mr. Packer has been the Chief Executive Officer and a director of ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions that was publicly traded until it was acquired by Asahi Kasei Corporation in April 2012. He served as Chairman of ZOLL from 1999 until November 2010. From 1996 until his appointment as Chairman and Chief Executive Officer in 1999, Mr. Packer served as ZOLL’s President, Chief Operating Officer and director. From 1992 to 1996, he served as Vice President of Operations of ZOLL and also served as Chief Financial Officer and Head of North American Sales of ZOLL from 1995 to 1996. Prior to joining ZOLL, Mr. Packer served for five years as Vice President of various functions for Whistler Corporation, a consumer electronics company. Before joining Whistler in 1987, Mr. Packer was a manager with the consulting firm of PRTM/KPMG, specializing in operations of high technology companies. Mr. Packer is the past Chairperson of MassMEDIC, the industry council for Medical Devices in Massachusetts. He currently serves as a board member of the Massachusetts Medical Device Development Center, a University of Massachusetts initiative to incubate medical device companies. Mr. Packer holds a M.B.A. from the Harvard Business School, as well as B.S. and M. Eng. degrees from Rensselaer Polytechnic Institute. Mr. Packer has extensive financial, operations and management experience in the medical devices industry. He also brings to the board significant experience in corporate governance, strategic planning and public company compensation matters. Mr. Packer serves on the Company’s Audit Committee and is the chairman of the Company’s Nominating Committee.
Dr. Requardt currently serves as an independent strategic advisor to a number of European public and private life science and healthcare technology companies. From 2009 to February 2015 he served as Chief Executive Officer of the healthcare division of Munich, Germany-based Siemens AG. He also served as Chief Technology Officer of Siemens AG from 2008 through 2011. Additionally, from 2006 through January 2015 he was a member of the Siemens AG Managing Board, during which time he also held a variety of regional and operational responsibilities at Siemens and its affiliates. Dr. Requardt joined Siemens Medical Solutions in 1984 and served there in roles of increasing responsibility before assuming global responsibility for the magnetic resonance business unit in 1994. Dr. Requardt is an honorary Professor of Physics at the University of Frankfurt and serves on several academic and industrial boards in Germany, including, among other positions, serving as Vice Chairman of Fraunhofer-Gesellschaft, Europe’s largest application-oriented research organization, and as a member of the Executive Board of Acatech, the National Academy of Science and Engineering. He also is a member of the Advisory Board of Dekra SE, headquartered in Stuttgart, Germany, and the Supervisory Board of Sivantos Group, which was Siemens Audiology Solutions prior to its spin-off from Siemens AG in early 2015. Dr. Requardt holds a Ph.D. in Biophysics, with a focus on radiation biophysics and microbiology, from the University of Frankfurt.
Dr. Munch has served since September 2012 as President, Bruker Nano Group, with responsibility for management of the global operations of our Bruker Nano Group, which manufactures and distributes the Company’s advanced analytical X-ray technologies and spark-optical emission spectroscopy, atomic force microscopy and stylus and optical metrology instrumentation used in non-destructive molecular, materials and elemental analysis. Dr. Munch has also served as President of Bruker Nano, Inc., a wholly-owned subsidiary of the Company, since October 2010. Prior to joining Bruker Nano, Inc., from February 2008 to October 2010 Dr. Munch was Executive Vice President of Veeco Instruments Inc. Dr. Munch has also served as a Senior Vice President of Coherent, Inc. from February 2006 to January 2008 and as President and Chief Executive Officer of Cooligy, Inc., a subsidiary of Emerson Electric, from 2004 to 2006. Dr. Munch’s background includes over 23 years of experience in marketing, product development, operations and sales, as well as experience in managing significant business units of multi-national corporations. Dr. Munch holds a Bachelor of Science degree in Chemical Engineering from the University of Colorado and a Master of Science degree and Ph.D. in Chemical Engineering from Stanford University.
Mr. Srega joined the Company as President, Bruker CALID Group in January 2013. In this position Mr. Srega is responsible for management of the global operations of our Bruker CALID Group, which manufactures and distributes the Company’s mass spectrometry and chromatography instruments for life science and applied markets, as well as analytical instruments for chemical, biological, radiological, nuclear and explosives detection and research and process instruments based on infrared and Raman molecular spectroscopy technologies. Prior to joining the Company, Mr. Srega served since 1996 in a variety of senior management roles at Thermo Fisher Scientific Inc., a global provider of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics headquartered in Waltham, Massachusetts. At Thermo Fisher Scientific, Mr. Srega led a number of significant operating divisions, including as Vice President and General Manager Biomarkers, BRAHMS GmbH, from 2011 to 2012, Vice President and General Manager Scientific Instruments Division Global Products from 2005 to 2011 and Vice President and General Manager Advanced MS from 1996 to 2004. Prior to 1996, Mr. Srega was with Badenwerk AG, a German power utility company located in Karlsruhe, Germany, from 1988 to 1995 and an employee of Bruker GmbH from 1980 to 1988. Mr. Srega holds a B.A. in Finance from Nord Akademie in Hamburg, Germany and a B.A. in Engineering from Karlsruhe University of Applied Sciences in Karlsruhe, Germany.